Nothing Special   »   [go: up one dir, main page]

HRP20220263T1 - Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi - Google Patents

Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi Download PDF

Info

Publication number
HRP20220263T1
HRP20220263T1 HRP20220263TT HRP20220263T HRP20220263T1 HR P20220263 T1 HRP20220263 T1 HR P20220263T1 HR P20220263T T HRP20220263T T HR P20220263TT HR P20220263 T HRP20220263 T HR P20220263T HR P20220263 T1 HRP20220263 T1 HR P20220263T1
Authority
HR
Croatia
Prior art keywords
compound
image
pharmaceutically acceptable
phenyl
methyl
Prior art date
Application number
HRP20220263TT
Other languages
English (en)
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20220263T1 publication Critical patent/HRP20220263T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Claims (11)

1. Spoj formule [image] naznačen time što R je odabran iz grupe koja se sastoji od [image] X je CH ili N; R1 je vodik ili fluoro; i R2 je C1 do C3 alkil; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, formule [image] naznačen time što R je odabran iz grupe koja se sastoji od [image] X je CH ili N; R1 je vodik ili fluoro; i R2 je C1 do C3 alkil; ili njegova farmaceutski prihvatljiva sol.
3. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što, R je [image]
4. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što, X je CH ili N; R1 is vodik ili fluoro; i R2 je metil ili izopropil.
5. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 ili 2 naznačen time što, R je [image]
6. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je 3-amino-6-[4-[[(2R)-2-(3,5-difluorofenil)-2-hidroksi-acetil]amino]-2-metil-fenil]-N-metilpirazin-2-karboksamid, koji je predstavljen formulom [image] ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je 2-amino-5-[4-[[(2R)-2-(3,5-difluorofenil)-2-hidroksi-acetil]amino]-2-metil-fenil]-N-izopropil-piridin-3-karboksamid, koji je predstavljen formulom [image] ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2 koji je (2R)-N-[4-(4-amino-7-metil-pirolo[2,3-d]pirimidin-5-il)-3-metil-fenil]-2-(3-fluorofenil)-2-hidroksi-acetamid, koji je predstavljen formulom [image] ili njegova farmaceutski prihvatljiva sol.
9. Farmaceutska kompozicija koja sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1-8, sa jednim ili više farmaceutski prihvatljivih nosača, razblaživača ili ekscipijenasa.
10. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1-8, za uporabu u terapiji.
11. Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1-8, za uporabu u liječenju raka gušterače.
HRP20220263TT 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi HRP20220263T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18
EP18718570.7A EP3612519B1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Publications (1)

Publication Number Publication Date
HRP20220263T1 true HRP20220263T1 (hr) 2022-04-29

Family

ID=58606227

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220263TT HRP20220263T1 (hr) 2017-04-18 2018-04-11 Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi

Country Status (28)

Country Link
US (2) US11655214B2 (hr)
EP (2) EP4039675B1 (hr)
JP (2) JP7110232B2 (hr)
KR (2) KR20230129627A (hr)
CN (2) CN110831927B (hr)
AU (2) AU2018255191B2 (hr)
BR (1) BR112019021867A2 (hr)
CA (1) CA3060564A1 (hr)
CO (1) CO2019012767A2 (hr)
CR (1) CR20190519A (hr)
CY (1) CY1125150T1 (hr)
DK (2) DK3612519T3 (hr)
ES (1) ES2906847T3 (hr)
FI (1) FI4039675T3 (hr)
HR (1) HRP20220263T1 (hr)
HU (1) HUE057745T2 (hr)
IL (2) IL270005B (hr)
LT (2) LT3612519T (hr)
MX (2) MX2019012428A (hr)
PH (1) PH12019502363A1 (hr)
PL (1) PL3612519T3 (hr)
PT (2) PT3612519T (hr)
RS (2) RS62933B1 (hr)
SA (1) SA519410320B1 (hr)
SG (1) SG11201909680UA (hr)
SI (2) SI4039675T1 (hr)
WO (1) WO2018194885A1 (hr)
ZA (1) ZA201906811B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018255191B2 (en) * 2017-04-18 2022-04-21 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
BR112020019023A2 (pt) 2018-03-26 2020-12-29 Icahn School Of Medicine At Mount Sinai Métodos de tratamento do câncer residual mínimo
WO2021041970A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
US20220348584A1 (en) 2019-08-29 2022-11-03 Hibercell, Inc. Perk inhibiting indolinyl compounds
JP2022546410A (ja) * 2019-08-29 2022-11-04 ヒベルセル, インコーポレイテッド Perk阻害化合物
CN114710956A (zh) * 2019-08-29 2022-07-05 希伯塞尔股份有限公司 抑制perk的吡咯并嘧啶化合物
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
WO2024206890A1 (en) * 2023-03-30 2024-10-03 Hibercell, Inc. Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337529A (en) 1997-03-19 2000-10-27 Basf Ag Pyrrolo[2,3-d]pyrimidine derivatives useful as tyrosine kinase inhibitors
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
US9586967B2 (en) 2013-11-08 2017-03-07 Ono Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
JP2017507967A (ja) 2014-03-11 2017-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Perk阻害剤として作用する化合物
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
MX2018001032A (es) * 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
CN109153680B (zh) 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
US20190241573A1 (en) 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
AU2018255191B2 (en) 2017-04-18 2022-04-21 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EP3709998B1 (en) 2017-11-14 2024-08-14 Children's Medical Center Corporation N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
BR112020019023A2 (pt) 2018-03-26 2020-12-29 Icahn School Of Medicine At Mount Sinai Métodos de tratamento do câncer residual mínimo
AU2019297428C1 (en) 2018-07-06 2023-03-23 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
JP7331212B2 (ja) 2023-08-22
US20230373922A1 (en) 2023-11-23
CN110831927A (zh) 2020-02-21
PH12019502363A1 (en) 2020-12-07
PT3612519T (pt) 2022-02-22
RS65914B1 (sr) 2024-10-31
CO2019012767A2 (es) 2020-04-01
EP4039675A1 (en) 2022-08-10
ZA201906811B (en) 2021-01-27
IL270005B (en) 2022-01-01
CN110831927B (zh) 2023-07-14
AU2022206702A1 (en) 2022-08-11
PT4039675T (pt) 2024-09-16
KR20190140966A (ko) 2019-12-20
AU2018255191A1 (en) 2019-11-07
FI4039675T3 (fi) 2024-09-10
MX2019012428A (es) 2022-01-28
LT3612519T (lt) 2022-03-25
SI3612519T1 (sl) 2022-04-29
MX2022001310A (es) 2022-03-02
EP3612519B1 (en) 2021-12-01
JP7110232B2 (ja) 2022-08-01
IL288822B2 (en) 2023-06-01
AU2022206702B2 (en) 2024-04-11
BR112019021867A2 (pt) 2020-05-26
KR20230129627A (ko) 2023-09-08
HUE057745T2 (hu) 2022-06-28
JP2022141835A (ja) 2022-09-29
US11655214B2 (en) 2023-05-23
SI4039675T1 (sl) 2024-10-30
WO2018194885A1 (en) 2018-10-25
RU2019136694A3 (hr) 2021-05-19
ES2906847T3 (es) 2022-04-20
CA3060564A1 (en) 2018-10-25
IL288822A (en) 2022-02-01
DK4039675T3 (da) 2024-09-02
EP4039675B1 (en) 2024-06-12
EP3612519A1 (en) 2020-02-26
RU2019136694A (ru) 2021-05-18
JP2021517555A (ja) 2021-07-26
US20210114985A1 (en) 2021-04-22
SG11201909680UA (en) 2019-11-28
AU2018255191B2 (en) 2022-04-21
CY1125150T1 (el) 2023-06-09
RS62933B1 (sr) 2022-03-31
LT4039675T (lt) 2024-10-10
CR20190519A (es) 2020-03-06
DK3612519T3 (da) 2022-03-07
PL3612519T3 (pl) 2022-05-02
KR102575246B1 (ko) 2023-09-06
CN117510405A (zh) 2024-02-06
SA519410320B1 (ar) 2022-05-08

Similar Documents

Publication Publication Date Title
HRP20220263T1 (hr) Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
EA034243B9 (ru) Фармацевтические композиции, содержащие azd9291, для лечения рака
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
RU2019106484A (ru) Гетероциклическое соединение
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
BR112014025564A2 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
EA201792559A1 (ru) Фармацевтические композиции для местного применения
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
JP2014511891A5 (hr)
GEP20247646B (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
AR103680A1 (es) Inhibidores selectivos de bace1
RU2018147263A (ru) Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные
JP2016501185A5 (hr)
PH12016502353A1 (en) Pharmaceutical composition
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
SA521422467B1 (ar) مركبات هالو-آلِّيلامين واستخدامها
EA201692298A1 (ru) Производные карбоксамидов